查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867242

良性前列腺增生治疗市场依药物类别、学名药状态、通路及剂型划分－2025年至2032年全球预测

Benign Prostatic Hypertrophy Drugs Market by Drug Class, Generic Status, Distribution Channel, Dosage Form - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

良性前列腺增生治疗市场预计到 2032 年将成长至 95.9 亿美元，复合年增长率为 7.18%。

关键市场统计数据
基准年 2024 55亿美元
预计年份：2025年 58.9亿美元
预测年份 2032 95.9亿美元
复合年增长率 (%) 7.18%

权威深入分析了影响良性前列腺增生药物治疗方法和获取趋势的临床、监管和商业性因素。

本执行摘要探讨了良性前列腺增生药物治疗领域复杂的临床、监管和商业性环境，特别关注人口老化、临床指南不断更新以及供应链现状变化等因素交织的影响。治疗环境面临药物安全性审查日益严格、现有药物专利专利到期以及对兼顾疗效和耐受性的联合治疗日益增长的需求等挑战。说明将整合活性成分组合、处方实践和分销模式的最新进展，为评估政策、投资和研发决策的相关人员提供一个连贯的观点。

简要回顾良性前列腺增生治疗领域中正在重新定义治疗策略、治疗途径和竞争动态的关键临床、商业性和监管转折点

良性前列腺增生（BPH）的治疗格局正在经历一场变革，这反映了医疗保健、药物研发和患者参与等方面的更广泛变化。关键的转变包括从单一疗法转向联合疗法，以寻求在症状控制和延缓疾病进展方面产生协同效应。同时，植物疗法的实证基础日益成熟，真实世界数据（RWE）也越来越多地被纳入疗效比较评估中，从而拓展了治疗选择并影响了处方行为。

评估2025年关税对良性前列腺增生治疗药物的购买、生产韧性和商业性准备的影响

2025年实施的关税及相关贸易政策措施，给药品供应链带来了日益复杂的局面，并对生产决策、筹资策略和库存管理产生了连锁反应。关税有可能增加进口原料药和成品药的到岸成本，迫使生产商重新评估采购方案、优化生产布局并重新谈判供应商合约。在价格和报销受到严格监管的地区，这些额外的成本压力可能会挤压利润空间，促使企业提高效率，并加快生产在地化进程，以降低外部贸易摩擦的风险。

将药物分类、学名药状态、通路和剂型特征与处方行为、获取途径和产品策略联繫起来的详细細項分析

治疗领域细分揭示了临床和商业性动态的差异，这对于贯穿研发、商业化和分销的策略规划至关重要。依药物类别划分，产品组合涵盖5α-还原酶抑制剂、α阻断剂、联合治疗和植物疗法。 5α-还原酶抑制剂类别的特征是具有不同的活性分子，例如度他雄胺和非那雄胺，每种分子都具有不同的药物动力学特性和现有的临床数据，这些都会影响处方医生的选择。 α受体阻断剂涵盖多种药物，包括阿夫唑嗪、多沙唑嗪、西洛多辛、Tamsulosin和特拉唑嗪，选择性谱和不利事件决定了特定患者表型的治疗选择。联合治疗方案包括5α-还原酶抑制剂与选择性α阻断剂的合併用药；常见的合併用药包括度他雄胺+Tamsulosin和非那雄胺+Tamsulosin。这些组合疗法旨在既能即时缓解症状，又能长期缩小摄护腺体积。植物疗法，例如β-谷甾醇、非洲臀果木和锯棕榈，仍然是寻求辅助或替代疗法的患者以及将患者意愿纳入共同决策的临床医生可行的选择。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在良性前列腺增生症的治疗中，新型β3促效剂疗法因其能促进膀胱平滑肌鬆弛而得到更广泛的应用。
  • 扩展一个整合远端监测和患者报告结果的数位健康平台，用于良性前列腺增生症治疗评估。
  • 前列腺动脉栓塞术作为一种微创手术，逐渐成为传统良性前列腺增生（BPH）手术的替代方案。
  • 开发一种联合治疗通讯协定，利用5α-还原酶抑制剂和植物化学萃取物来增强前列腺体积缩小效果。
  • 越来越重视生物标记和基因谱分析，以实现良性前列腺增生症药物治疗方案的个人化。
  • 评估选择性雄性激素调变器以缓解良性前列腺增生症状和减少性副作用的临床试验激增

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 良性摄护腺增生药物市场（依药物类别划分）

  • 5α-还原酶抑制剂
    • 度他雄胺
    • 非那雄胺
  • α受体阻断剂
    • 阿夫唑嗪
    • 多沙唑嗪
    • 西洛多辛
    • Tamsulosin
    • 特拉唑嗪
  • 联合治疗
    • 度他雄胺+Tamsulosin
    • 非那雄胺+Tamsulosin
  • 植物疗法
    • β-谷甾醇
    • 非洲臀果木
    • 锯棕榈

第九章 良性摄护腺增生治疗市场（依学名药类别划分）

  • 品牌产品
    • 阿伏达特
    • 弗洛马克斯
    • 贾林
    • 保列治
  • 非专利的

第十章 良性摄护腺增生治疗市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 良性摄护腺增生治疗市场（依剂型划分）

  • 胶囊
    • 缓释性
    • 快速起效配方
  • 口服液
  • 药片
    • 缓释性
    • 快速起效配方

第十二章 良性摄护腺增生治疗市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 良性摄护腺增生治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国良性摄护腺增生治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Viatris Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Cipla Limited
    • Lupin Limited
Product Code: MRR-CB04E056547E

The Benign Prostatic Hypertrophy Drugs Market is projected to grow by USD 9.59 billion at a CAGR of 7.18% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.50 billion
Estimated Year [2025] USD 5.89 billion
Forecast Year [2032] USD 9.59 billion
CAGR (%) 7.18%

An authoritative orientation to the clinical, regulatory, and commercial factors reshaping therapeutic approaches and access dynamics for benign prostatic hypertrophy drugs

This executive summary introduces the complex clinical, regulatory, and commercial environment surrounding pharmacologic management of benign prostatic hypertrophy, emphasizing the confluence of aging demographics, evolving clinical guidelines, and shifting supply chain realities. It situates the therapeutic landscape within an era of intensified scrutiny over drug safety profiles, patent expirations for legacy agents, and rising interest in combination regimens that aim to balance efficacy with tolerability. The narrative that follows synthesizes recent developments in active ingredient portfolios, prescribing practices, and distribution modalities to provide a cohesive perspective for stakeholders evaluating policy, investment, or R&D decisions.

The introduction recognizes the heterogeneity of patient journeys-from initial symptom management to advanced intervention-and underscores how therapeutic choice is increasingly influenced by comorbidity management, polypharmacy concerns, and patient preferences for convenience and quality of life. Clinical guidelines continue to refine criteria for intervention, while payers and providers reassess treatment pathways to optimize outcomes and cost-effectiveness. In parallel, innovation is concentrated on improving adherence through formulation science and on identifying complementary therapies that mitigate adverse effects of standard agents. This section frames the subsequent analysis by highlighting the principal forces that are likely to drive strategic priorities across industry, clinical practice, and regulatory spheres.

A concise exploration of the pivotal clinical, commercial, and regulatory transitions that are redefining therapeutic strategies, access, and competitive dynamics for BPH treatments

The landscape for benign prostatic hypertrophy therapeutics has undergone transformative shifts that reflect broader changes across healthcare delivery, drug development, and patient engagement. Key shifts include a move from single-agent paradigms toward combination strategies that seek synergistic gains in symptom control and disease progression mitigation. This is complemented by a parallel maturation of evidence around phytotherapeutic options and the integration of real-world evidence into comparative effectiveness assessments, which together broaden therapeutic choice and influence prescribing behavior.

Another transformative element is the rapid digitization of the patient journey, which has altered how prescriptions are accessed, refilled, and monitored. Telehealth consultations and digital adherence tools are increasingly common, prompting manufacturers and distributors to re-evaluate channels for patient support programs and post-marketing surveillance. Regulatory environments have also evolved, with authorities emphasizing pharmacovigilance and clearer benefit-risk communication, particularly for agents with long-term exposure in older populations. In addition, intellectual property transitions and the rise of high-quality generics are intensifying competition and prompting lifecycle strategies focused on formulation improvements, combination approvals, and line extensions. Collectively, these shifts compel manufacturers, payers, and clinicians to reassess clinical value propositions and to prioritize interventions that demonstrably improve long-term patient outcomes while maintaining affordability and access.

An assessment of how 2025 tariff measures influenced pharmaceutical sourcing, manufacturing resilience, and commercial readiness for benign prostatic hypertrophy therapeutics

The imposition of tariffs and related trade policy measures in 2025 introduced incremental complexity into the supply chain for pharmaceuticals, with cascading effects on manufacturing decisions, procurement strategies, and inventory management. Tariffs can increase landed costs for imported active pharmaceutical ingredients and finished dosage forms, prompting manufacturers to review sourcing options, re-optimize production footprints, and renegotiate supplier contracts. In jurisdictions where pricing and reimbursement are tightly regulated, these added cost pressures can compress margins, catalyze efficiency drives, and accelerate efforts to localize manufacturing to reduce exposure to external trade friction.

Beyond direct cost implications, tariffs have also influenced the cadence of regulatory submissions and contract negotiations. Procurement officers and health systems have increasingly factored geopolitical risk into multi-year supplier agreements and contingency planning, driving a preference for diversified supplier networks and buffer inventories. For manufacturers, the response has included greater emphasis on supply chain resilience through dual sourcing, strategic stockpiling of critical intermediates, and investment in regional production capabilities. Importantly, these adaptations affect more than cost lines; they shape product availability, launch sequencing for new formulations or combination therapies, and the competitive landscape as some firms are better positioned to absorb or mitigate tariff-related disruptions. In sum, tariff dynamics in 2025 acted as an accelerant for strategic realignment across sourcing, manufacturing, and commercialization decisions within the therapeutic area.

In-depth segmentation narrative linking drug classes, generic status, distribution channels, and dosage form attributes to prescribing behavior, access pathways, and product strategies

Segmentation of the therapeutic domain reveals differentiated clinical and commercial dynamics that are essential for strategic planning across development, commercialization, and distribution. Based on drug class, the portfolio spans 5-alpha reductase inhibitors, alpha blockers, combination therapy, and phytotherapy. The 5-alpha reductase inhibitors category is characterized by distinct active molecules such as dutasteride and finasteride, each with divergent pharmacokinetic properties and legacy clinical data that influence prescriber choice. Alpha blockers encompass a spectrum of agents including alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin, where selectivity profiles and adverse event considerations drive therapeutic selection for specific patient phenotypes. Combination therapy options pair a 5-alpha reductase inhibitor with a selective alpha blocker, with commonly observed pairings involving dutasteride plus tamsulosin and finasteride plus tamsulosin; these combinations are positioned to address both immediate symptom relief and longer-term prostate volume reduction. Phytotherapeutic alternatives-such as beta-sitosterol, pygeum, and saw palmetto-remain relevant for patients seeking complementary or alternative approaches and for clinicians who integrate patient preference into shared decision-making.

Based on generic status, the landscape comprises both branded and generic offerings, with branded agents including noted trade names that have historically shaped prescribing habits and promotional approaches. Patent expirations and the ensuing generic entries have prompted lifecycle management strategies among originators, including reformulation, indication consolidation, and patient support initiatives. Based on distribution channel, treatment access is mediated through hospital pharmacies, online pharmacies, and retail pharmacies; each channel has its own dynamics around procurement cycles, patient counseling opportunities, and reimbursement interactions. Based on dosage form, therapeutic presentations include capsules, oral solutions, and tablets, with formulations differentiated by release profile-capsules and tablets are available in extended release and immediate release variants-affecting adherence, dosing convenience, and tolerability profiles. Recognizing these segmentation nuances is critical for aligning product development, commercial messaging, and distribution strategies with clinician needs and patient expectations.

A regional synthesis highlighting how regulatory diversity, reimbursement frameworks, and healthcare infrastructure drive distinct access and adoption patterns across global territories

Regional differences materially shape how therapies are developed, approved, reimbursed, and ultimately accessed by patients, with each geographic area presenting distinct regulatory, payer, and clinical practice realities. In the Americas, healthcare systems vary from publicly funded national programs to predominantly private insurance frameworks, influencing formulary negotiation approaches, tendering practices, and the adoption timeline for combination therapies and novel formulations. Reimbursement mechanisms and clinical guideline endorsements interact to determine how quickly new evidence is translated into changes in standard practice.

In Europe, the Middle East & Africa region, a mosaic of regulatory regimes and reimbursement environments requires tailored market access strategies that account for divergent price controls, varying levels of pharmacovigilance infrastructure, and differing capacities for local manufacturing. This complexity often necessitates regionalized clinical evidence generation and adaptive commercial models that reflect the heterogeneity of payer expectations. In the Asia-Pacific region, high population growth, increasing healthcare investment, and accelerating digital health adoption are creating fertile conditions for expanded access models, greater emphasis on cost-effective generics, and the rapid scaling of e-prescription and online pharmacy channels. Across all regions, local clinical guidelines, demographic trends, and supply chain capabilities are primary determinants of product uptake and long-term positioning.

An analytical overview of competitive approaches and strategic maneuvers by incumbent and emerging companies shaping product differentiation and market positioning

Competitive dynamics in this therapeutic area reflect a mix of established pharmaceutical firms with legacy branded assets and agile generic manufacturers and specialty companies pursuing niche positioning. Incumbent originator companies continue to leverage clinical legacy, physician relationships, and brand recognition, while generics manufacturers focus on cost competitiveness, reliable supply, and partnerships with distributors and procurement consortia. Innovation is observable in areas such as fixed-dose combination approvals, reformulated extended-release products, and patient support services designed to improve adherence and persistence.

Strategic collaborations and licensing arrangements are increasingly prominent as a way to accelerate geographic expansion and to share risk related to manufacturing localization or regulatory submissions. Companies that invest in clinical evidence demonstrating improved outcomes with combination regimens or novel formulations tend to achieve stronger clinician buy-in. At the same time, those that can integrate digital support tools, curated educational content for prescribers, and real-world data capture into their go-to-market strategies create differentiated value propositions that extend beyond price-focused competition. The interplay between brand stewardship and cost-effective manufacturing capability will remain central to competitive performance in the near term.

A set of practical, high-impact strategic moves for manufacturers, payers, and distributors to strengthen resilience, clinical value, and uptake of BPH treatment options

Industry leaders should prioritize a portfolio of actions designed to enhance resilience, clinical relevance, and commercial differentiation. First, aligning clinical development and post-marketing evidence generation with real-world effectiveness and safety endpoints will strengthen value narratives with payers and prescribers. Demonstrating tangible benefits of combination regimens or new formulations in routine care settings will facilitate guideline incorporation and payer acceptance. Second, optimizing supply chain architecture to reduce exposure to single-source dependencies and trade-related shocks will protect product availability; strategies include regional manufacturing partnerships, dual sourcing of key intermediates, and collaborative inventory management with major distributors.

Third, investment in digital patient engagement and adherence technologies should be treated as a core component of product launch and lifecycle programs rather than an adjunct activity, because these tools can materially improve persistence and support outcome-based contracting. Fourth, tailored access strategies that reflect regional regulatory and reimbursement realities-ranging from evidence packages for health technology assessment committees to flexible pricing arrangements-will be essential to unlocking adoption across diverse jurisdictions. Finally, companies should explore targeted alliances with clinical centers and professional societies to co-create educational initiatives that address appropriate patient selection and long-term management, thereby elevating both clinical practice and product uptake.

A transparent methodological synopsis describing qualitative and secondary research integration, data validation approaches, and limitations to support reproducibility and strategic interpretation

The analysis underpinning this report synthesizes multiple research approaches to ensure robust, actionable insights. Primary research elements included structured interviews with clinical experts, formulary decision-makers, procurement leads, and specialty pharmacists to capture contemporary practice patterns and payer expectations. These qualitative inputs were complemented by targeted interviews with manufacturing and supply chain executives to understand sourcing strategies and capacity considerations. Secondary research incorporated regulatory documents, clinical trial registries, and peer-reviewed clinical literature to triangulate efficacy, safety, and guideline trends.

Data integrity was maintained through cross-validation of stakeholder claims against publicly available regulatory communications and clinical evidence. The methodology emphasized transparency in assumptions and documented limitations, including recognition of geographic variability in data availability. Where applicable, synthesis prioritized recent peer-reviewed findings and government-issued guidance to reflect current standards of care and regulatory priorities. Throughout the research process, ethical considerations guided outreach and data handling, and methodological choices were designed to support reproducibility and relevance to strategic decision-making.

A conclusive synthesis that distills implications for stakeholders and outlines the strategic levers necessary to convert emerging trends into sustainable clinical and commercial advantages

In conclusion, the therapeutic landscape for benign prostatic hypertrophy is being reshaped by convergent forces: clinical preferences shifting toward combination strategies, regulatory emphasis on safety and long-term outcomes, and commercial pressures arising from intellectual property transitions and supply chain volatility. These dynamics create both challenges and opportunities for stakeholders seeking to advance patient care while maintaining sustainable commercial models. Resilience in manufacturing and supply, strategic evidence generation, and patient-centric engagement will be the differentiators that determine which products and companies achieve durable success.

Looking ahead, organizations that proactively adapt to regional regulatory nuances, integrate digital adherence solutions, and align clinical development with real-world outcomes will be best positioned to influence standards of care and secure durable partnerships with payers and healthcare systems. Cross-functional collaboration-linking R&D, regulatory affairs, supply chain, and commercial teams-will be essential to translate insight into execution and to ensure that innovations meaningfully improve patient experiences and clinical endpoints.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of novel B3 agonist therapies targeting bladder smooth muscle relaxation in BPH management
  • 5.2. Expansion of digital health platforms integrating telemonitoring and patient reported outcomes in BPH therapy assessment
  • 5.3. Emergence of prostate arterial embolization as a minimally invasive alternative to traditional BPH surgical procedures
  • 5.4. Development of combination therapy protocols involving 5a reductase inhibitors with phytochemical extracts for enhanced prostate volume reduction
  • 5.5. Increasing focus on biomarkers and genetic profiling to personalize benign prostatic hyperplasia pharmacotherapy approaches
  • 5.6. Surge in clinical trials evaluating selective androgen receptor modulators to mitigate BPH symptoms with fewer sexual side effects

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Benign Prostatic Hypertrophy Drugs Market, by Drug Class

  • 8.1. 5-Alpha Reductase Inhibitors
    • 8.1.1. Dutasteride
    • 8.1.2. Finasteride
  • 8.2. Alpha Blockers
    • 8.2.1. Alfuzosin
    • 8.2.2. Doxazosin
    • 8.2.3. Silodosin
    • 8.2.4. Tamsulosin
    • 8.2.5. Terazosin
  • 8.3. Combination Therapy
    • 8.3.1. Dutasteride + Tamsulosin
    • 8.3.2. Finasteride + Tamsulosin
  • 8.4. Phytotherapy
    • 8.4.1. Beta-Sitosterol
    • 8.4.2. Pygeum
    • 8.4.3. Saw Palmetto

9. Benign Prostatic Hypertrophy Drugs Market, by Generic Status

  • 9.1. Branded
    • 9.1.1. Avodart
    • 9.1.2. Flomax
    • 9.1.3. Jalyn
    • 9.1.4. Proscar
  • 9.2. Generic

10. Benign Prostatic Hypertrophy Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Benign Prostatic Hypertrophy Drugs Market, by Dosage Form

  • 11.1. Capsule
    • 11.1.1. Extended Release
    • 11.1.2. Immediate Release
  • 11.2. Oral Solution
  • 11.3. Tablet
    • 11.3.1. Extended Release
    • 11.3.2. Immediate Release

12. Benign Prostatic Hypertrophy Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Benign Prostatic Hypertrophy Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Benign Prostatic Hypertrophy Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Merck & Co., Inc.
    • 15.3.2. GlaxoSmithKline plc
    • 15.3.3. Teva Pharmaceutical Industries Ltd.
    • 15.3.4. Novartis AG
    • 15.3.5. Boehringer Ingelheim International GmbH
    • 15.3.6. Viatris Inc.
    • 15.3.7. Sun Pharmaceutical Industries Ltd.
    • 15.3.8. Dr. Reddy's Laboratories Ltd.
    • 15.3.9. Cipla Limited
    • 15.3.10. Lupin Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, B